Incyte Corporation

74.88+0.5400+0.73%Vol 1.26M1Y Perf -10.98%
May 20th, 2022 16:00 DELAYED
BID71.00 ASK82.00
Open75.03 Previous Close74.34
Pre-Market- After-Market74.88
 - -  - -%
Target Price
87.42 
Analyst Rating
Moderate Buy 2.00
Potential %
16.75 
Finscreener Ranking
★★★★+     55.62
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★★+     59.06
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★★     77.37
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
49.22 
Earnings Rating
Strong Buy
Market Cap16.59B 
Earnings Date
3rd May 2022
Alpha-0.01 Standard Deviation0.09
Beta0.71 

Today's Price Range

72.8275.14

52W Range

61.9188.26

5 Year PE Ratio Range

-44.50283.60

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-0.75%
1 Month
-5.55%
3 Months
8.48%
6 Months
15.24%
1 Year
-10.98%
3 Years
-3.24%
5 Years
-43.44%
10 Years
241.79%

TickerPriceChg.Chg.%
INCY74.880.54000.73
AAPL137.590.24000.17
GOOG2 186.26-28.6500-1.29
MSFT252.56-0.5800-0.23
XOM91.860.72000.79
WFC41.67-0.3300-0.79
JNJ176.983.04001.75
FB193.542.25001.18
GE75.25-0.4900-0.65
JPM117.34-0.9700-0.82
Financial StrengthValueIndustryS&P 500US Markets
3.50
3.70
0.01
0.01
257.50
Leverage Ratio 1.30
ProfitabilityValueIndustryS&P 500US Markets
94.70
18.40
20.40
2.70
29.77
RevenueValueIndustryS&P 500US Markets
3.11B
14.06
14.26
18.47
Earnings HistoryEstimateReportedSurprise %
Q01 20220.340.4017.65
Q04 20210.65-0.07-110.77
Q03 20210.551.0081.82
Q02 20210.540.6520.37
Q01 20210.420.5019.05
Q04 20200.650.7312.31
Q03 20200.480.03-93.75
Q02 20200.681.0452.94
Earnings Per EndEstimateRevision %Trend
6/2022 QR0.6127.08Positive
9/2022 QR0.6643.48Positive
12/2022 FY2.31-13.48Negative
12/2023 FY3.702.78Positive
Next Report Date-
Estimated EPS Next Report0.34
Estimates Count4
EPS Growth Next 5 Years %36.00
Volume Overview
Volume1.26M
Shares Outstanding221.51K
Shares Float182.61M
Trades Count20.72K
Dollar Volume93.96M
Avg. Volume1.36M
Avg. Weekly Volume1.29M
Avg. Monthly Volume1.34M
Avg. Quarterly Volume1.44M

Incyte Corporation (NASDAQ: INCY) stock closed at 74.34 per share at the end of the most recent trading day (a 1.29% change compared to the prior day closing price) with a volume of 1.38M shares and market capitalization of 16.59B. Is a component of S&P 500, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 1773 people. Incyte Corporation CEO is Herve Hoppenot.

The one-year performance of Incyte Corporation stock is -10.98%, while year-to-date (YTD) performance is 1.28%. INCY stock has a five-year performance of -43.44%. Its 52-week range is between 61.91 and 88.26, which gives INCY stock a 52-week price range ratio of 49.22%

Incyte Corporation currently has a PE ratio of 17.80, a price-to-book (PB) ratio of 4.29, a price-to-sale (PS) ratio of 5.30, a price to cashflow ratio of 21.90, a PEG ratio of 2.32, a ROA of 21.92%, a ROC of 27.97% and a ROE of 28.98%. The company’s profit margin is 29.77%, its EBITDA margin is 20.40%, and its revenue ttm is $3.11 Billion , which makes it $14.06 revenue per share.

Of the last four earnings reports from Incyte Corporation, there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.34 for the next earnings report. Incyte Corporation’s next earnings report date is -.

The consensus rating of Wall Street analysts for Incyte Corporation is Moderate Buy (2), with a target price of $87.42, which is +16.75% compared to the current price. The earnings rating for Incyte Corporation stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Incyte Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Incyte Corporation has a Sell technical analysis rating based on Technical Indicators (ADX : 12.08, ATR14 : 2.32, CCI20 : -99.46, Chaikin Money Flow : 0.07, MACD : -0.85, Money Flow Index : 45.87, ROC : -3.68, RSI : 45.42, STOCH (14,3) : 23.58, STOCH RSI : 0.55, UO : 48.52, Williams %R : -76.42), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Incyte Corporation in the last 12-months were: Barry P. Flannelly (Option Excercise at a value of $2 950 627), Barry P. Flannelly (Sold 43 993 shares of value $3 672 887 ), Dashyant Dhanak (Sold 1 569 shares of value $123 387 ), Jonathan Elliott Dickinson (Sold 7 375 shares of value $547 151 ), Maria E. Pasquale (Option Excercise at a value of $41 634), Paul Trower (Option Excercise at a value of $601 347), Paul Trower (Sold 8 214 shares of value $602 168 ), Paula J. Swain (Option Excercise at a value of $1 577 309), Paula J. Swain (Sold 20 189 shares of value $1 481 453 ), Vijay K. Iyengar (Sold 4 911 shares of value $384 482 ), Wendy L. Dixon (Option Excercise at a value of $1 465 000), Wendy L. Dixon (Sold 20 000 shares of value $441 000 ), Wenqing Yao (Sold 27 194 shares of value $2 321 551 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
7 (53.85 %)
7 (53.85 %)
7 (50.00 %)
Moderate Buy
1 (7.69 %)
1 (7.69 %)
1 (7.14 %)
Hold
4 (30.77 %)
4 (30.77 %)
5 (35.71 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
1 (7.69 %)
1 (7.69 %)
1 (7.14 %)
Summary RatingModerate Buy
2.00
Moderate Buy
2.00
Moderate Buy
2.07

Incyte Corporation

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). Incyte's pipeline includes a broad array of oncology and dermatology programs.

CEO: Herve Hoppenot

Telephone: +1 302 498-6700

Address: 1801 Augustine Cut-Off, Wilmington 19803, DE, US

Number of employees: 1 773

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

60%40%

Bearish Bullish

63%37%

Bearish Bullish

59%41%

TipRanks News for INCY

Mon, 11 Apr 2022 16:05 GMT Incyte (INCY) Gets a Buy Rating from JMP Securities

- TipRanks. All rights reserved.

Mon, 14 Mar 2022 16:15 GMT Incyte (INCY) Gets a Hold Rating from Mizuho Securities

- TipRanks. All rights reserved.

Thu, 10 Feb 2022 05:35 GMT Incyte (INCY) Receives a Buy from JMP Securities

- TipRanks. All rights reserved.

Thu, 10 Feb 2022 02:09 GMT Incyte (INCY) Receives a Hold from Stifel Nicolaus

- TipRanks. All rights reserved.

Thu, 27 Jan 2022 05:15 GMT Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and Cortexyme (CRTX)

- TipRanks. All rights reserved.

Tue, 18 Jan 2022 09:15 GMT Analysts Have Conflicting Sentiments on These Healthcare Companies: Incyte (INCY) and Cytokinetics (CYTK)

- TipRanks. All rights reserved.

Thu, 13 Jan 2022 06:45 GMT Analysts Opinions Are Mixed on These Healthcare Stocks: Biogen (BIIB), Incyte (INCY) and InflaRx (IFRX)

- TipRanks. All rights reserved.

Thu, 06 Jan 2022 06:12 GMT What Does Incytes Newly Added Risk Factor Reveal

- TipRanks. All rights reserved.

News

Stocktwits